Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

Dane Cheasley, Abhimanyu Nigam, Magnus Zethoven, +18

The Journal of Pathology

Oestrogen ReceptorOncologyTumor HeterogeneityCdkn2a Protein LossGenomic Analysis +11

A microfluidic chip based model for the study of full thickness human intestinal tissue using dual flow

Amy Dawson, Charlotte E. Dyer, John Macfie, +4

Biomicrofluidics

Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Marta Llauradó Fernández, Gabriel E. DiMattia, Amy Dawson, +10

PubMed

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

Marta Llauradó Fernández, Amy Dawson, Joshua Hoenisch, +12

Cancer Cell International

Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma

Marta Llauradó Fernández, Amy Dawson, Hannah Kim, +15

Gynecologic Oncology

Hormone Receptor ExpressionMedicineHormonal ReceptorGynecologyPathology +6

Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

Raunak Shrestha, Marta Llauradó Fernández, Amy Dawson, +17

Cancer Research

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

Dane Cheasley, Marta Llauradó Fernández, Martin Köbel, +16

npj Precision Oncology

Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes

Stephanie Scott, Marta Llauradó Fernández, Hannah Kim, +19

Gynecologic Oncology

Surgical OncologyCancer EpidemiologyMedicinePractice PatternsCancer Management +8

Lab-on-a-chip workshop activities for secondary school students

Mohammad Mehdi Esfahani, Mark D. Tarn, Tahmina A. Choudhury, +7

Biomicrofluidics

EngineeringEducationOrgan-on-a-chipBiological MaterialsBiomedical Engineering +20

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Marta Llauradó Fernández, E. Marielle Hijmans, Annemiek M.C. Gennissen, +17

Molecular Cancer Therapeutics

Signaling PathwayMeki ResistanceEpithelial Ovarian CancerMedicineReceptor Tyrosine Kinase +12